LONGITUDINAL CHANGES IN MULTIPLE BIOMARKERS ARE ASSOCIATED WITH CARDIOTOXICITY IN BREAST CANCER PATIENTS TREATED WITH DOXORUBICIN, TAXANES AND TRASTUZUMAB

被引：0
|
作者：
Hahn, Virginia Shalkey
Putt, Mary
Sawaya, Heloisa
Januzzi, James
Sebag, Igal A.
Plana, Juan
Picard, Michael
Gerszten, Robed
Halpern, Elkan
Kuter, Irene
Martin, Randolph
Carver, Joseph
Scherrer-Crosbie, Marielle
Ky, Bonnie
机构：
[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2015年 / 65卷 / 10期
关键词：
D O I：
10.1016/S0735-1097(15)61001-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1217-224
引用
收藏
页码：A1001 / A1001
页数：1
相关论文
共 50 条
  • [31] Fcγ-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab.
    Cresti, N.
    Jamieson, D.
    Verrill, M. W.
    Pinkilgton, M.
    Boddy, A. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Cardiotoxicity risks of adjuvant trastuzumab in Asian breast cancer patients
    Shih, V.
    Chan, A.
    Chiang, J.
    Teo, C.
    Chen, J.
    Wong, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Cardiotoxicity among patients with breast cancer treated with doxorubicin: A real-world database study
    Manohar, Poorni
    Linden, Hannah M.
    Hess, Lisa M.
    Sugihara, Tomoko
    Zhu, Yajun E.
    Muntz, Howard G.
    Cranmer, Lee D.
    CANCER RESEARCH, 2021, 81 (04)
  • [34] Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
    Schultink, Aurelia H. M. de Vries
    Boekhout, Annelies H.
    Gietema, Jourik A.
    Burylo, Artur M.
    Dorlo, Thomas P. C.
    van Hasselt, J. G. Coen
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (03) : 431 - 442
  • [35] Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
    Fiúza M.
    Advances in Therapy, 2009, 26 (Suppl 1) : S9 - S17
  • [36] Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
    Aurelia H. M. de Vries Schultink
    Annelies H. Boekhout
    Jourik A. Gietema
    Artur M. Burylo
    Thomas P. C. Dorlo
    J. G. Coen van Hasselt
    Jan H. M. Schellens
    Alwin D. R. Huitema
    Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45 : 431 - 442
  • [37] Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab
    Pistillucci, G.
    Ciorra, A. A.
    Sciacca, V.
    Raponi, M.
    Rossi, R.
    Veltri, E.
    CLINICA TERAPEUTICA, 2015, 166 (01): : E67 - E71
  • [38] Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer
    Suter, TM
    Cook-Bruns, N
    Barton, C
    BREAST, 2004, 13 (03): : 173 - 183
  • [39] CARDIOTOXICITY PHENOTYPES IN WOMEN TREATED WITH ANTHRACYCLINES AND TRASTUZUMAB FOR EARLY STAGE BREAST CANCER
    Nolan, Mark T.
    Selam, Mustafa Abdul
    Amir, Eitan
    Koch, Anne
    Yip, Paul
    Michalowska, Maria
    Wintersperger, Bernd
    Thavendiranathan, Paaladinesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 799 - 799
  • [40] Alcohol and HERZ Polymorphisms as Risk Factor for Cardiotoxicity in Breast Cancer Treated with Trastuzumab
    Lemieux, Julie
    Diorio, Caroline
    Cote, Marc-Andre
    Provencher, Louise
    Barabe, Frederic
    Jacob, Simon
    St-Pierre, Christine
    Demers, Eric
    Tremblay-Lemay, Rosemarie
    Nadeau-Larochelle, Corinne
    Michaud, Annick
    Laflamme, Christian
    ANTICANCER RESEARCH, 2013, 33 (06) : 2569 - 2576
12345